Basic Information
The company provides proprietary knockdown™ technologies, such as antisense molecules (i.e., geneblocs®), improved synthetic siRNA, vector expression systems for siRNA and ribozymes, and superior transfection reagents. Atugen AG has established various collaborations with major pharmaceutical and biotechnology companies, ranging from fee-for-service structures to strategic alliances, to discover and validate gene targets for drug discovery.